CytoDyn (CYDY) Revenue (2021 - 2022)
CytoDyn (CYDY) posted Revenue of $34000.0 for Q2 2022, down 84.89% on a QoQ basis from $225000.0 in Q4 2021.
CytoDyn (CYDY) Revenue (2021 - 2022) Analysis & Trends
CytoDyn's Revenue history runs 2 years deep, the most recent figure standing at $34000.0 for Q2 2022.
- Quarterly Revenue changed N/A year-over-year to $34000.0 in Q2 2022, while the trailing twelve-month figure through May 2022 was $300000.0 (changed N/A YoY) and the FY2022 annual result came in at $300000.0, changed N/A from the prior year.
- Revenue was $34000.0 for Q2 2022 at CytoDyn, down from $225000.0 in the prior quarter.
- Across five years, Revenue topped out at $225000.0 in Q4 2021 and bottomed at $34000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | CytoDyn | 248.66 Mn | 248.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2022 | 34,000.00 |
| Nov 30, 2021 | 225,000.00 |
| Aug 31, 2021 | 41,000.00 |